PortfoliosLab logoPortfoliosLab logo
ISIN
US97382D3035
CUSIP
97382D303
IPO Date
Aug 8, 1995

Highlights

Market Cap
$402.79
Enterprise Value
$6.30M
EPS (TTM)
-$2.59K
Total Revenue (TTM)
$90.00K
Gross Profit (TTM)
$11.00K
EBITDA (TTM)
-$11.77M
Year Range
$0.01 - $1.86
ROA (TTM)
-255.62%
ROE (TTM)
-453,955.56%

Share Price Chart


Loading charts...

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Windtree Therapeutics Inc

Performance

WINT Performance Chart

Windtree Therapeutics Inc (WINT) is down 52.8% since the beginning of the year. At $0 per share, WINT is trading 99.2% below its 52-week high of $2. Investors who bought $1,000 worth of WINT shares 5 years ago would now be looking at an investment worth $0.


Loading charts...

S&P 500 Index

Returns By Period

Windtree Therapeutics Inc (WINT) has returned -52.78% so far this year and -98.09% over the past 12 months. Over the last ten years, WINT has returned -84.75% per year, falling short of the S&P 500 Index benchmark, which averaged 13.66% annually.


Windtree Therapeutics Inc

1D
2.37%
1M
-31.36%
YTD
-52.78%
6M
-70.74%
1Y
-98.09%
3Y*
-97.71%
5Y*
-95.84%
10Y*
-84.75%

Benchmark (S&P 500 Index)

1D
-0.74%
1M
4.90%
YTD
10.35%
6M
10.28%
1Y
26.52%
3Y*
20.83%
5Y*
12.30%
10Y*
13.66%
*Multi-year figures are annualized to reflect compound growth (CAGR)

WINT Monthly Returns History

Based on dividend-adjusted daily data since Jan 4, 2016, WINT's average daily return is -0.32%, while the average monthly return is -7.35%.

Historically, 30% of months were positive and 70% were negative. The best month was Apr 2020 with a return of +214.3%, while the worst month was Aug 2025 at -85.9%. The longest winning streak lasted 3 consecutive months, and the longest losing streak was 11 months.

On a daily basis, WINT closed higher 36% of trading days. The best single day was Apr 30, 2020 with a return of +200.0%, while the worst single day was Aug 20, 2025 at -77.2%.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2026-45.99%-38.62%1.89%131.48%-43.20%6.34%-52.78%
2025-62.61%-51.30%-60.38%-7.14%-34.96%-32.18%30.81%-85.91%-29.26%55.42%-58.60%-26.15%-99.82%
2024-41.54%-14.35%-1.67%-20.51%-29.50%-10.10%184.11%-11.07%-70.53%-70.57%-24.65%-34.09%-97.30%
2023-5.88%-21.50%-20.54%-67.13%-21.95%-2.34%11.20%-20.78%-13.86%10.69%7.62%-36.37%-91.54%
2022-29.60%-5.31%6.54%-35.12%-34.15%-14.37%-5.52%0.00%-23.83%-42.85%12.24%-11.69%-89.41%
20218.58%-8.44%-51.96%-9.39%-20.27%29.38%-17.47%3.70%5.10%-13.59%-3.93%-6.14%-68.71%

Benchmark Metrics

Windtree Therapeutics Inc has an annualized alpha of -59.56%, beta of 0.75, and R2 of 0.01 versus S&P 500 Index. Calculated based on daily prices since January 05, 2016.

  • This stock participated in 233.18% of S&P 500 Index downside but only -165.82% of its upside - more exposed to losses than it benefited from rallies.
  • R2 of 0.01 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

Alpha
-59.56%
Beta
0.75
0.01
Upside Capture
-165.82%
Downside Capture
233.18%

Return for Risk

Risk / Return Rank

WINT ranks 14 for risk / return — in the bottom 14% of stocks on our site. This means you're taking on significantly more risk than the returns justify. Consider whether the potential upside is worth the volatility, or explore alternatives with better risk / return profiles.


WINT Risk / Return Rank: 1414
Overall Rank
WINT Sharpe Ratio Rank: 2222
Sharpe Ratio Rank
WINT Sortino Ratio Rank: 1414
Sortino Ratio Rank
WINT Omega Ratio Rank: 1515
Omega Ratio Rank
WINT Calmar Ratio Rank: 22
Calmar Ratio Rank
WINT Martin Ratio Rank: 1717
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

Return / Risk — by metrics

The table below present risk-adjusted performance metrics for Windtree Therapeutics Inc (WINT) and compare them to S&P 500 Index.


WINTBenchmarkDifference
Sharpe ratioReturn per unit of total volatility

-2.69

Sortino ratioReturn per unit of downside risk

-3.91

Omega ratioGain probability vs. loss probability

0.90

1.41

-0.51

Calmar ratioReturn relative to maximum drawdown

-0.99

2.93

-3.92

Martin ratioReturn relative to average drawdown

-1.13

13.52

-14.65

Dividends

Dividend History


Windtree Therapeutics Inc doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading charts...

Worst Drawdowns

The table below displays the maximum drawdowns of the Windtree Therapeutics Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Windtree Therapeutics Inc was 100.00%, occurring on Feb 10, 2026. The portfolio has not yet recovered.

The current Windtree Therapeutics Inc drawdown is 100.00%.


Related event

Drawdown

Fall

Recovery

Underwater

2026 bear market2026
-100.00%Feb 2026
9y 10mo
10y 1moApr 2016 - now
2016 bear market2016
-46.26%Mar 2016
2mo 12d25d
3mo 7dJan 2016 - Apr 2016
2016 pullback2016
-0.66%Apr 2016
0s1d
1dApr 2016 - Apr 2016

Drawdown Indicators


WINTBenchmarkDifference

Max Drawdown

Largest peak-to-trough decline

-100.00%

-56.78%

-43.22%

Max Drawdown (1Y)

Largest decline over 1 year

-99.29%

-9.10%

-90.19%

Max Drawdown (3Y)

Largest decline over 3 years

-100.00%

-18.90%

-81.10%

Max Drawdown (5Y)

Largest decline over 5 years

-100.00%

-25.43%

-74.57%

Max Drawdown (10Y)

Largest decline over 10 years

-100.00%

-33.92%

-66.08%

Current Drawdown

Current decline from peak

-100.00%

-0.74%

-99.26%

Average Drawdown

Average peak-to-trough decline

-90.52%

-10.72%

-79.80%

Ulcer Index

Depth and duration of drawdowns from previous peaks

86.88%

1.97%

+84.91%

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading charts...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Windtree Therapeutics Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Valuation

The Valuation section provides an overview of how Windtree Therapeutics Inc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for WINT relative to other companies in the Biotechnology industry. Currently, WINT has a P/S ratio of 0.0. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for WINT in comparison with other companies in the Biotechnology industry. Currently, WINT has a P/B value of 0.1. This P/B ratio is low compared to industry peers. It might indicate the stock is undervalued or that the company’s assets are not expected to generate strong returns.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items
Portfolio Analyzer

Build a portfolio with WINT

Add Windtree Therapeutics Inc to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Analyzer with WINT